April 11, 2012 Dick Menzies, MD Montreal Chest Institute, McGill University

Size: px
Start display at page:

Download "April 11, 2012 Dick Menzies, MD Montreal Chest Institute, McGill University"

Transcription

1 MDR-TB, XDR-TB, and TDR-TB. Is this April 11, 2012 Dick Menzies, MD Montreal Chest Institute, McGill University MDR XDR TDR What s in a name? Dr Dick Menzies Le Chest (McGill, Montreal) 1

2 Disclaimer I have no financial conflicts of interest (sadly) Global TB Impact The World Health Organization estimates that: 1.6 million TB deaths. 8.8 million cases of new TB. 20 million persons living with active TB. 2 billion persons with latent or dormant infection. 200 million will develop active TB over next 20 years 2

3 Recent trends in Global TB: Global incidence increased rapidly in 1990 s Then by 0.4% annually Now has levelled off or slight decline Globally number of cases still increasing slightly or levelled off High-income countries: Decreasing rates Former Soviet Union From 1990 until 2002 increased 12% / year Sub-Saharan Africa Increasing 6% / year How much drug resistance is there? And how does this develop? 3

4 Rate of spontaneous mutations to different anti-tb drugs (From in-vitro experiments) Streptomycin 10-6 Isoniazid Rifampicin Ethambutol INH&Rif

5 Number of bacilli by clinical extent of disease Extent Quantity State Granuloma 103 latent TB Infiltrates AFB Neg Culture Pos Cavity AFB +, ++ Many cavities, Death 1013 rigor mortis Probability that resistance will develop by number of bacilli and of drugs Medication Quantity of Bacilli Strep solo 50% 100% 100% 100% INH solo 10% 90% 100% 100% RIF solo 0% 10% 90% 100% INH&RIF 0% 0% 0% 10% 5

6 Treatment with Streptomycin alone, or PAS alone % Patients with resistance - Days after Tx started Source: Rieder, Interventions for TB control, IUATLD. Treating TB with one drug Improvement then worsening the fall and rise phenomenon Source: Toman Case Finding and Chemotherapy 6

7 Transient drug resistance during therapy with two or more drugs (effect of default) From Toman, Case Finding and Chemotherapy 13 Emergence of Drug resistance Single drug therapy inevitably leads to resistance Even two-drug therapy will often lead to resistance Irregular therapy also leads to selection of resistant strains: Low dose therapy will lead to DR All conditions are common in many countries Low quality drugs Inadequate regimens prescribed Patients have to buy meds = irregular and mono Poor follow-up = interrupted therapy (often many times) 7

8 TB treatment and Drug resistance a short history 1943 Streptomycin found to be active against M tuberculosis 1944 First clinical experience - Rapid improvement, but rapid development of resistance new TB drugs developed, tested, and introduced. Concept of multi-drug therapy 1970 RIF introduced most effective TB drug MDR = Res to INH& RIF recognized in new TB drug developed, tested and introduced (FQN) Part 1 - MDR-TB 8

9 MDR-TB definition Resistance to INH and RIF Most effective and well tolerated TB drugs Before RIF was available, TB therapy was months So given lack of new drugs Have to go back to the old drugs MDR-TB treatment Prolonged current minimum is 18 months Unpleasant current minimum is 6 months of injectable Toxic use second line drugs many more adverse effects Ineffective Cure rates 50-60% in 3 recent reviews 9

10 MDR treatment controversies Duration How long to treat? 12 months vs 18 vs 24 months Injectable 3-4 months vs 6 months or longer How many drugs? 3 vs 4 vs 5? Which drugs? Which injectable? 10

11 MDR treatment the evidence There are NO randomized trials Many cohorts with different approaches, populations and results Local experience shapes expert opinions And experience varies widely In the absence of evidence opinions get stronger First try: Classic meta-analysis of studies of MDR-TB treatment Three were completed in All based on observational studies Most cohorts received individualized therapy This made pooling of results difficult 11

12 Traditional systematic review in MDR-TB Characteristics and outcomes Variable Cohorts Default/ N treated Pooled default Estimate 95% CI % Female 0-28% / % / % / Not reported 5 97/ Traditional systematic review in MDR-TB History and outcomes % prior treatment Cohorts Default/ N treated Pooled default Estimate 95% CI 0 33% 7 271/ % / % / Not reported 6 69/

13 Traditional systematic review in MDR-TB Treatment and outcomes % receiving fluoroquinolones Cohorts Death/ N treated Pooled death Estimate 95% CI 0 48% 12 92/ % / % - 100% / Not reported / Problems of traditional systematic reviews in MDR-TB Treatment is individualized - in most series, and most patients. Patients are very different in same centre, and between centres Clinical characteristics (history, age, HIV) Drug resistance Hence can only analyze % with resistance, or % getting Drug X Can only detect very large effects 13

14 Second try: Individual Patient data meta-analysis Background Study initiated in response to WHO desire to update MDR treatment Expert group consulted to list the most important questions in MDR treatment 14

15 IPD Objectives Which are the most (and least) effective drugs for MDR-TB treatment? What is the optimal number of drugs? Overall (total) Intensive phase What is the optimal duration of treatment? Initial intensive phase (duration of Injectable) Total duration Methods 15

16 Study (data-set) Selection Study Eligible if: Included in one of 3 systematic reviews of MDR treatment Johnston (published 2009) Orenstein (published 2009) Akcakir (McGill MSc thesis, completed 2009) Inclusion criteria of these 3 reviews: Report of original data, published since 1970 At least one reported treatment outcome that conformed with established definitions for success, failure, relapse, death, or default All patients had bacteriological confirmation of TB, and confirmed INH and RIF resistance Studies excluded if only XDR-TB patients Data Collection Patient-level information Patient factors Treatment outcomes Age at time of diagnosis Sex HIV infection ART use Clinical factors Site of disease AFB smear results Culture results Chest X-ray (cavitations) Drug Sensitivity Testing (DST) - Initial & repeat First line DST results Second line DST results Treatment Factors Initial phase treatment regimen (drugs and duration) Continuation phase treatment regimen (drugs and duration) Modifications to treatment (in response to DST, or AE) Adverse events Surgical resection 16

17 Data Management Mapped and renamed original variables to common set of variables for pooled metaanalysis dataset Individual data dictionaries Completed variable extraction forms Authors contacted for missing data, clarify variables, verify certain results. Summary tables of clinical characteristics of the study population in each study compared with original publications Variables provided in few data sets were noted, but not analysed. Meta-analysis Random effects logistic regression to obtain the odds of cure for each drug - in all patients and among patients with MTB that was sensitive to drug of interest Multivariate approach: Pooled estimates calculated using PROC GLIMMIX in SAS a random effects logistic regression model Covariates: Age, Gender, HIV, Extent of disease (AFB smear/cxr cavities), and Past TB treatment (none, previous TB treatment, previous MDR-TB treatment) Heterogeneity examined using Forest plots, I 2, and τ 2 statistics 17

18 3 Systematic reviews identified Orenstein, Johnston, Akcakir 93 studies identified from 3 systematic reviews 67 individual cohorts 32 data sets included in this analysis, with 9898 patients Study Selection Excluded: 26 publications representing the same or overlapping cohorts Excluded - 35 cohorts 13 No author response 8 No longer have access to data 5 Inadequate outcome data 2 Refusals 2 No response following initial contact 2 No data on drug sensitivity testing 2 Data never sent 1 Cohort with less than 25 patients 9153 patients analyzed Excluded Patients XDR TB Extra-pulmonary TB No treatment info Patient Characteristics full data set 6742 (68%) male patients 6283 (63%) prior TB treatment 1193 (12%) HIV co-infection at MDR-TB diagnosis 16 patients received ART 9200 (93%) pulmonary TB 6425 (65%) AFB smear-positive 5081 (51%) cavitations on chest x-ray 18

19 Overall Treatment Outcomes Cure/completed (54%) Failure (7%) Relapse - 90 (1%) (but only 11/32 (34%) studies reported) Death (16%) Default (22%) Which drugs? Drug-by-drug analysis First Line Agents Injectables Fluoro-Quinolones Group 4 Drugs Group 5 drugs 19

20 First Line Agents Pyrazinamide had minimal impact of borderline statistical significance for one outcome Ethambutol had no significant effects on any outcome First line drug vs. no first line drug Success vs. Fail/Relapse aor (95% CI) Success vs. Fail/Relapse/Death aor (95% CI) Success vs. Fail/Relapse/ Death/Default OR (95% CI) Pyrazinamide 1.2 (0.9, 1.7) 1.3 (1.1, 1.6) 1.1 (0.9, 1.4) Ethambutol 0.9 (0.7, 1.1) 0.8 (0.7, 1.0) 0.9 (0.8, 1.2) Injectables Kanamycin / Amikacin Capreomycin 20

21 Kanamycin only vs. Capreomycin only Kanamycin only Capreomycin only Total Cured Success vs. Fail/Relapse N Unadjusted 1.0 (ref) 0.5 (0.3, 0.7) Adjusted (0.3, 0.7) Success vs. Fail/Relapse/Death N Unadjusted 1.0 (ref) 0.5 (0.4, 0.7) Adjusted (0.4, 0.8) Success vs. Fail/Relapse/Death/Default N Unadjusted 1.0 (ref) 0.7 (0.6, 0.8) Adjusted (0.6, 0.9) Kanamycin only vs. Capreomycin only In Kanamycin Sensitive* strains only Kanamycin only Capreomycin only Total Cured Success vs. Fail/Relapse N Unadjusted 1.0 (ref) 0.6 (0.4, 1.1) Adjusted (0.3, 1.1) Success vs. Fail/Relapse/Death N Unadjusted 1.0 (ref) 0.7 (0.5, 0.96) Adjusted (0.5, 1.1) Success vs. Fail/Relapse/Death/Default N Unadjusted 1.0 (ref) 0.7 (0.5, 0.9) Adjusted (0.6, 1.05) *if patient missing Kanamycin DST result and < 10% fellow cohort members resistant, then imputed that patient was sensitive to Kanamycin 21

22 Kanamycin only vs. Capreomycin only, among only Kanamycin resistant patients Kanamycin only Capreomycin only Total Cured Success vs. Fail/Relapse N Unadjusted 1.0 (ref) 2.7 ( ) Adjusted 2.3 ( ) Success vs. Fail/Relapse/Death N Unadjusted 1.0 (ref) 1.5 (0.8, 3.0) Adjusted (0.8, 3.2) Success vs. Fail/Relapse/Death/Default N Unadjusted 1.0 (ref) 1.6 (0.9, 2.8) Adjusted (0.9, 2.9) Fluoro-quinolones Ofloxacin Later generation (Moxifloxacin, and Levofloxacin 22

23 Fluoro-Quinolones (FQ) Ofloxacin, Ciprofloxacin, and higher generation FQ were all superior to no FQ among FQ-sensitive patients FQ vs. no FQ Success vs. Fail/Relapse OR (95% CI) Success vs. Fail/Relapse/ Death OR (95% CI) Success vs. Fail/Relapse/ Death/Default OR (95% CI) Ofloxacin 2.5 (1.6, 3.9) 2.3 (1.4, 3.8) 2.0 (1.2, 3.3) High Quinolone 2.5 (1.6, 3.9) 2.7 (1.7, 4.3) 3.1 (2.0, 4.8) Fluoro-Quinolones (FQ) Higher generation FQs performed better than Ofloxacin across all 3 outcomes High FQ vs. Ofloxacin Success vs. Fail/Relapse OR (95% CI) Success vs. Fail/Relapse/Death OR (95% CI) Success vs. Fail/Relapse/ Death/Default OR (95% CI) 1.7 (1.1, 2.7) 2.0 (1.4, 3.1) 1.9 (1.3, 2.6) 23

24 Group 4 drugs PAS Cycloserine Ethionamide/Prothionamide Group 4 Drugs Ethionamide/Prothionamide was the most effective drug Cycloserine showed borderline effectiveness for one of the three outcomes Group 4 drug vs. no Group 4 drug Success vs. Fail/Relapse OR (95% CI) Success vs. Fail/Relapse/ Death OR (95% CI) Success vs. Fail/Relapse/ Death/Default OR (95% CI) Ethionamide/ 1.7 (1.3, 2.3) 1.7 (1.4, 2.1) 1.7 (1.5, 2.0) Prothionamide Cycloserine 1.1 (0.8, 1.7) 1.5 (1.0, 2.3) 1.5 (0.9, 2.2) PAS 0.9 (0.6, 1.4) 1.0 (0.8, 1.3) 1.1 (1.0, 1.4) 24

25 Group 5 drugs Clofazimine Thiacetazone Clarithromycin (or other Macrolides) Amoxy-Clavulanate Number of drugs and Duration Initial intensive phase (injectables) Continuation phase Total therapy 25

26 Effect of number of susceptible drugs in initial phase on Cure/complete vs fail/relapse I sq: 0 (0, 0.25) N of drugs Total treated Cured Pooled adjusted odds of cure N N N (%) OR (95% CI) (82%) 1.0 Reference (91%) 2.0 (1.3, 3.2) (91%) 1.9 (1.2, 3.1) (92%) 2.3 (1.2, 4.3) Effect of number of susceptible drugs in continuation phase on cure/complete vs fail/relapse I sq: 0 (0, 0.38) N of drugs Total treated Cured Pooled adjusted odds of cure N N N (%) OR (95% CI) % 1.0 reference % 2.5 (1.6, 3.8) % 2.7 (1.6, 4.4) % 1.9 (1.0, 3.7) 26

27 Duration of Initial Phase and Success vs. Fail/Relapse (ALL patients) Months N Adjusted Model (reference) (0.5, 3.2) (1.2, 4.2) (2.0, 7.3) (1.9, 11.8) (1.2, 3.8) Total Duration of therapy and Success vs. Fail/Relapse (All patients) Months N Adjusted Model (reference) (0.6, 3.6) (1.5, 8.7) (2.0, 11.5) (2.1, 11.5) (4.5, 30.2) (1.0, 7.6) (0.2, 5.8) 27

28 Conclusions of IPD Current Recommendations* Initial phase 3 6 months Continuation phase months 3 5 additional drugs *2008 Emergency Update from WHO IPD Evidence Initial phase months 4 effective drugs Continuation phase months 3 effective drugs FQ especially later FQ Eto/Pto Kanamycin Part 2: XDR Setting: rural South Africa Incidence of TB 1,100 / 100,000 annually Or, 1.1% of total population develops TB each year!! >80% are HIV co-infected All TB drugs available Non-completion very common Outbreak: 80 HIV-TB patients at 1 hospital Same strain of TB = nosocomial outbreak Extensive drug resistance 79/80 die 28

29 Looking for XDR Definition of XDR = MDR plus resistance to FQ and at least one second line injectable Data- set established to study MDR-TB 9153 patients with MDR-TB 410 found to have XDR!! Cases going back to 1990 s Describing XDR How bad is it? What makes it bad? The FQ resistance The injectables Or both Data set had: 410 with XDR 424 with MDR and FQN resistance 1129 with Second line injectable resistance 29

30 Clinical characteristics of MDR patients with different resistance patterns. (From simple pooling across all studies) (Percentages are of patients in each group where information was available) XDR MDR- FQR MDR- INJR MDR only Prior TB Therapy NONE 16% 19% 24% 20% FLD only 57% 64% 60% 73% SLD (MDR) 27% 17% 16% 7% Resection Surgery 17% 7% 13% 5% Serious AE 32% 43% 47% 29% Overall outcomes by MDR group XDR MDR-FQR MDR-INJR MDR only # of Studies # of Patients Pooled Outcomes Meta- analysis by study Cured 40% (27, 53) 48% (36, 60) 56% (45, 66) 64% (57, 72) Fail/Relapse 22% (15, 28) 18% (14, 21) 12% (9, 15) 4% (2, 6) Died 15% (8, 23) 11% (3, 19) 8% (3, 14) 8% (5, 11) Surgery 16% (8, 24) 12% (1,23) 16% (7, 24) 18% (12,24) SAE 7% (0.18) 11% (0.25) 9% (1, 17) 5% (0,10) 30

31 Number of likely effective drugs during initial phaseand odds of success Number XDR of drugs N aor (95% CI) (reference) (0.8, 4.3) (0.5, 6.6) (1.4, 16.6) Number of likely effective drugs during in continuation phase and odds of success Number XDR of drugs N aor (95% CI) (reference) (1.3, 8.5) (1.4, 26.3) (0.7, 7.6) 31

32 Impact of duration of Initial treatment on success vs Failure/Relapse Initial Duration XDR Months N aor (95% CI) (reference) (0.6, 62) (5.2, 200) (1.2, 21) Impact of Total duration of treatment on Odds of success vs Failure/Relapse Initial Duration XDR Months N aor (95% CI) (reference) (0.3,11.7) (1.7, 17.6) (1.3, 25.1) 32

33 Part 3: TDR Report from India: 6 patients resistant to all known TB drugs Poor outcomes Attracted HUGE media attention Usual doomsday sensationalist stories Bad press for Indian TB programme What is TDR? How to define? Depends on how much you test!! What are the outcomes? What determines prognosis? Resistance to which drugs? How to treat? 33

34 Looking for TDR Among the 400+ XDR patients there were many with Total Drug Resistance = resistant to all tested. Tried 3 different definitions: TDR1 XDR & resistant to Kana and Cap (and Sm if tested) TDR2 TDR1 & resistant to at least one Group 4 drug TDR3 TDR2 & resistant to EMB and/or PZA Definitions (used for analysis) Study population: 8955 DST for at least 1 FQN and 1 SLI: 6724 XDR: 405 (6% of MDR) TDR1: 68 TDR2: 48 TDR3: 42 (10% of XDR, 0.6% of MDR) Not TDR (but XDR):

35 Number of Drugs to which MTB organisms resistant by TDR groups (all have XDR) (1b) XDR but TDR1 TDR2 TDR3 Not TDR Total % 0% 10% 0% 6 31% 4% 27% 29% 7 31% 13% 8% 10% 8 18% 31% 6% 7% 9 10% 25% 4% 5% 10 1% 21% 35% 40% 11 0% 6% 8% 10% ODDS of Outcomes adjusted for individual characteristics - by TDR groups XDR but Not TDR TDR1 TDR2 TDR3 Total N Cured 1.0 (reference) 0.4 (0.2, 0.8) 0.6 (0.2, 1.6) 0.5 (0.2, 1.7) Failed 1.0 (reference) 2.1 (1.0, 4.5) 1.8 (0.7, 4.7) 1.9 (0.7, 5.3) Died 1.0 (reference) 1.6 (0.6, 4.4) 1.7 (0.6, 4.9) 1.8 (0.6, 5.3) Failed or Died 1.0 (reference) 2.6 (1.2, 4.4) 2.6 (1.1, 6.7) 2.8 (1.0, 7.9) 35

36 Outcomes pooling across studies (standard metaanalysis) - by TDR groups XDR but Not TDR TDR1 TDR2 TDR3 Total N Cured 43% (27, 58) 30% (17, 43) 34% (-, -)* 19% (0, 48) Failed 20% (15, 25) 29% (8, 50) 33% (-, -)* 26% (14, 38) Died 13% (6, 20) 18% (7, 29) 30% (18, 41) 35% (21, 50) Conclusions Treatment of drug-sensitive TB leads to MDR-TB Poor treatment leads faster and in more patients RIF containing regimens introduced in 1970 MDR described 20 years later Treatment of MDR-TB leads to XDR-TB Widespread treatment of MDR available since 2000 XDR described in 2006 (but present for years before) Treatment of XDR leads to TDR TDR described in 2011 (also present for years before Cure rates similar to historical spontaneous cure rates What's next? 36

37 Next steps New drugs at least two are needed TMC 207 (Tibotec) is the only one close to real use Others in pipeline at least 5 more years Better use of existing drugs High dose RIF Daily Rifapentine Other combinations Randomized trials Leadership Funding Collaboration Evidence base Phase 3 RCT in TB Number of Randomized trials of treatment in New cases by decade when they started enrolment 40 Number of studies 's 1960's 1970's 1980's 1990's 2000 Year study started Note: all but two of the RCT were publicly funded 37

38 40 Evidence base: Phase 3 RCT in Drug resistance / Re-treatment Number by decade when they started enrolment Number of studies 's 1960's 1970's 1980's 1990's 2000 Year study started To date no published RCT in MDR-TB We can do better!! Thank you Merci Gracias 38

39 Acknowledgements Melissa Bauer, Maria Graciela Holmes Delgado, Sandra Ramoutar, Lena Shah Andrea Benedetti The IPD Group The Collaborative Group for Meta-Analysis of Individual Patient Data in MDR-TB, Members (in alphabetic order): D. Ashkin, S.Ahuja, M. Avendano, M. Bauer, M. Becerra, A. Benedetti, M. Burgos, R. Centis, E. Chan, C.Y. Chiang, F. Cobelens, H. Cox, E. Declercq, D. Enarson, D. Falzon, K. Flanagan, J. Flood, J. Furin, L. Garcia-Garcia, N. Gandhi, P. Hopewell, T. Holtz, S. Keshavjee, WJ.Koh, V. Leimane, C.C. Leung, J. Li, A.K. Maug, D. Menzies, G.B. Migliori, C.Mitnick, S.S. Munsiff, M. Narita, E. Nathanson, P. O Riordan, M. Pai, D. Palmero, G. Pasvol, J. Pena, C. Perez, MID Quelapio, H.T. Quy, A. Ponce-de-Leon, V. Riekstina, J. Robert, S. Royce, M. Salim, H.S. Schaaf, K.J. Seung, L. Shah, K.P. Shean, T.S. Shim, S.S. Shin, Y. Shiraishi, Jose Sifuentes-Osornio, G. Sotgiu, M. Strand, P. Tabarsi, T.E. Tupasi, M. Vargas, M. Van der Walt, T.S. Van der Werf, A. Van Deun, P. Viiklepp, W.W. Yew, J.J. Yim 39

40 Treatment Outcome Definitions Treatment Cure: completion of treatment and consistent (at least 5 consecutive) culture negative results for the final 12 months of treatment or if the last two cultures before the end of treatment had negative results. Treatment Completed: completion of the assigned treatment without meeting the definition for cure or failure Treatment Default: interruption of MDR-TB treatment for 2 or more consecutive months for any reason, 1 month before the planned end of treatment without meeting the definition for cure or failure. (Included patients who transferred out of program or whose outcome was simply unknown.) Treatment Failure: At least 1 positive culture after 6 months or 2 or more positive results of the 5 cultures in the final 12 months of treatment, or if there was a clinical decision to stop treatment due to poor response or adverse events. Death: Death from any cause during treatment. Merci / thanks 40

Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.

Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant

More information

Treatment of INH Resistant-TB An aggregate data, and an Individual Patient Data (IPD) meta-analyses

Treatment of INH Resistant-TB An aggregate data, and an Individual Patient Data (IPD) meta-analyses Treatment of INH Resistant-TB An aggregate data, and an Individual Patient Data (IPD) meta-analyses Dick Menzies Montreal Chest Institute, McGill International TB Centre NAR Meeting Chicago, March 1-3,

More information

Pyrazinamide resistance in MDR and extensively drug-resistant tuberculosis.

Pyrazinamide resistance in MDR and extensively drug-resistant tuberculosis. Biomedical Research 2017; 28 (8): 3532-3536 ISSN 0970-938X www.biomedres.info Pyrazinamide resistance in MDR and extensively drug-resistant tuberculosis. Lan Yao, Qing Zhang, Yidan Liu, Heping Xiao * Tuberculosis

More information

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin

More information

Certainty assessment of patients Effect Certainty Importance. a standardised 9 month shorter MDR-TB regimen. e f

Certainty assessment of patients Effect Certainty Importance. a standardised 9 month shorter MDR-TB regimen. e f Author(s): STREAM Stage 1 Trial investigators reported for the Guideline Development Group for the WHO treatment guidelines on MDR/RR-TB, 2018 update (6 July 2018) - FINAL RESULTS Question: PICO 1. In

More information

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Managing Complex TB Cases Diana M. Nilsen, MD, RN Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private

More information

Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients

Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients Shama D. Ahuja 1, David Ashkin 2, Monika Avendano 3, Rita

More information

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH. The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,

More information

Evidence review for Intermittent therapy for drug-susceptible TB: Questions addressed: intermittent therapy

Evidence review for Intermittent therapy for drug-susceptible TB: Questions addressed: intermittent therapy Evidence review for Intermittent therapy for drug-susceptible TB: Dr. Dick Menzies Montreal Chest Institute, McGill University Montreal, Canada Questions addressed: intermittent therapy 1: Does intermittent

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment

More information

Annex 2. GRADE glossary and summary of evidence tables

Annex 2. GRADE glossary and summary of evidence tables WHO/HTM/TB/2011.6b. GRADE glossary and summary of evidence tables GRADE glossary Absolute effect The absolute measure of intervention effects is the difference between the baseline risk of an outcome (for

More information

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016 Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the

More information

Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore

Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Management of MDR TB Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore Outline Global epidemiology of Tuberculosis Epidemiology of Tuberculosis

More information

Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB)

Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) M Bonnet, M Bastard, P du Cros, K Atadjan, K Kimenye, S Khurkhumal, A Hayrapetyan, A Telnov, C Hewison, F Varaine

More information

Management of Drug-resistant Tuberculosis (DR-TB)

Management of Drug-resistant Tuberculosis (DR-TB) Management of Drug-resistant Tuberculosis (DR-TB) Nitipatana Chierakul Division of Respiratory Disease & Tuberculosis Department of Medicine Faculty of Medicine Siriraj Hospital October 14 th, 2008 Tropical

More information

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe

More information

Diagnosis and Treatment of Tuberculosis, 2011

Diagnosis and Treatment of Tuberculosis, 2011 Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is

More information

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Management of Multidrug- Resistant TB in Children Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Objectives To review data on best practices for diagnosis, treatment and prevention

More information

Short Course Treatment for MDR TB

Short Course Treatment for MDR TB Objectives Short Course Treatment for MDR TB Barbara J Seaworth M.D. Medical Director Heartland National TB Center Professor of Medicine, University of Texas Health Northeast Participants will utilize

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Günther G, Lange C, Alexandru S, et al. Treatment outcomes

More information

Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview

Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview Human Journals Review Article August 2016 Vol.:1, Issue:3 All rights are reserved by Mr. Suraj Narayan Mali et al. Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview Keywords: Totally Drug-resistant

More information

The shorter regimen for MDR-TB: evidence and pitfalls

The shorter regimen for MDR-TB: evidence and pitfalls The shorter regimen for MDR-TB: evidence and pitfalls Helen Cox 10 November 2017 What is the shortened regimen? Current conventional regimen (SA): Intensive Phase (at least 6 months): PZA / (EMB) / Kana

More information

Management of MDR TB in special situations. Dr Sarabjit Chadha The Union

Management of MDR TB in special situations. Dr Sarabjit Chadha The Union Management of MDR TB in special situations Dr Sarabjit Chadha The Union MDR TB in special situations Pregnancy Breastfeeding Contraception Renal Insufficiency Diabetes Pregnancy and TB Pregnancy is not

More information

Treatment of Tuberculosis

Treatment of Tuberculosis TB Clinical i l Intensive Seattle Treatment of Tuberculosis June 16, 2016 Masa Narita, MD Public Health Seattle & King County; Firland Northwest TB Center, University of Washington Outline Unique features

More information

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Neel R. Gandhi, MD Emory Rollins School of Public Health January 17, 2013 Medical Research Council BMJ 1948

More information

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries

More information

Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant

Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant Treatment outcomes and survival based on drug resistance patterns in multidrug-resistant tuberculosis Doh Hyung Kim, Hee Jin Kim, Seung-Kyu Park, Suck-Jun Kong, Young Sam Kim, Tae-Hyung Kim, Eun Kyung

More information

Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health

Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health Multiple Drug-resistant Tuberculosis: a Threat to Global - and Local - Public Health C. Robert Horsburgh, Jr. Boston University School of Public Health Background Outline Why does drug resistance threaten

More information

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words

More information

Predicting outcomes and drug resistance with standardised treatment of active tuberculosis

Predicting outcomes and drug resistance with standardised treatment of active tuberculosis Eur Respir J 21; 36: 87 877 DOI: 1.1183/931936.15179 CopyrightßERS 21 Predicting outcomes and drug resistance with standardised treatment of active tuberculosis O. Oxlade*,#, K. Schwartzman*,#, M. Pai*,#,

More information

Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis

Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis ERJ Express. Published on December 22, 2016 as doi: 10.1183/13993003.00993-2016 ORIGINAL ARTICLE TUBERCULOSIS Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis Greg

More information

Treatment of Active Tuberculosis

Treatment of Active Tuberculosis Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest

More information

Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa

Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa 2005 2010 BK Moore 1, E Anyalechi 1, M van der Walt 2, S Smith 1, L Erasmus 3, J Lancaster 2, S Morris 1, N Ndjeka

More information

Final Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR)

Final Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR) Final Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR) Tuberculosis (TB). AH Diacon*, A Pym**, MP Grobusch, G. Churchyard, T De

More information

HA Convention 2016 : Special Topic Session 3 May 2016

HA Convention 2016 : Special Topic Session 3 May 2016 HA Convention 2016 : Special Topic Session 3 May 2016 Diagnosis and Management of TB in Adults Dr. Thomas Mok COS(RMD), KH Tuberculosis An airborne infectious disease caused by Mycobacterium tuberculosis

More information

The emerging threat of multidrug resistant TB: Global and local challenges and solutions

The emerging threat of multidrug resistant TB: Global and local challenges and solutions Summary of IOM-ASSAf Workshop on: The emerging threat of multidrug resistant TB: Global and local challenges and solutions Salim S. Abdool Karim Pretoria - March, 2010 Why this workshop? Why is it on MDR

More information

Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India

Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India AGORA RESEARCH LETTER Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India To the Editor: Bedaquiline, a mycobacterial ATP synthase inhibitor [1], is the first

More information

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis

More information

Research in Tuberculosis: Translation into Practice

Research in Tuberculosis: Translation into Practice Case History Research in Tuberculosis: Translation into Practice This is a 6-year6 year-old Bosnian male, who presented to ER with one-week history of fever and occasional vomiting. No cough, difficulty

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis, 1940 s Treatment of Tuberculosis ATS/CDC/IDSA Joint Statement 2003 Saskatchewan Lung Association Outline, 2012 Treatment of Tuberculosis Principles of treatment of tuberculosis

More information

Diagnosis of drug resistant TB

Diagnosis of drug resistant TB Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million

More information

NIH Public Access Author Manuscript Int J Tuberc Lung Dis. Author manuscript; available in PMC 2013 August 06.

NIH Public Access Author Manuscript Int J Tuberc Lung Dis. Author manuscript; available in PMC 2013 August 06. NIH Public Access Author Manuscript Published in final edited form as: Int J Tuberc Lung Dis. 2013 May ; 17(5): 624 629. doi:10.5588/ijtld.12.0792. Outcomes of children treated for tuberculosis with second-line

More information

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 TB Nurse Case Management Davenport, Iowa September 27 28, 2011 Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011 Lisa Armitige, MD, PhD has the following disclosures to make:

More information

Pediatric TB Intensive San Antonio, Texas October 14, 2013

Pediatric TB Intensive San Antonio, Texas October 14, 2013 Pediatric TB Intensive San Antonio, Texas October 14, 2013 Treatment of Tuberculosis in Children Jeffrey R. Starke, M.D. Professor of Pediatrics October 14, 2013 Jeffrey R. Starke, M.D. has the following

More information

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY CHAPTER:1 TUBERCULOSIS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY GLOBAL EMERGENCY: * Tuberculosis kills 5,000 people a day! * 2.3 million die each year!

More information

Marcos Burgos, MD has the following disclosures to make:

Marcos Burgos, MD has the following disclosures to make: Guidelines for the Treatment of Tuberculosis Marcos Burgos, MD May 13, 2015 TB for Pulmonologist March 13, 2015 Phoenix, AZ EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures

More information

Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis

Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis Authors: Phan Thai (phanvuongkhacthai@yahoo.com) Dang Ha

More information

Soedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital

Soedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital Soedarsono Department of Pulmonology and Respiratory Medicine Faculty of Medicine, Universitas Airlangga Dr. Soetomo General Hospital MDR-TB is a public health crisis 480 000 people developed MDR-TB in

More information

WHO treatment guidelines for isoniazidresistant

WHO treatment guidelines for isoniazidresistant WHO treatment guidelines for isoniazidresistant tuberculosis Online Annexes: Supplement to the WHO treatment guidelines for drug-resistant tuberculosis WHO treatment guidelines for isoniazid-resistant

More information

Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB

Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Eur Respir J 2009; 33: 1085 1094 DOI: 10.1183/09031936.00155708 CopyrightßERS Journals Ltd 2009 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB K. Kliiman and

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict

More information

TUBERCULOSIS TREATMENT WITH MOBILE-PHONE MEDICATION REMINDERS IN NORTHERN THAILAND

TUBERCULOSIS TREATMENT WITH MOBILE-PHONE MEDICATION REMINDERS IN NORTHERN THAILAND Southeast Asian J Trop Med Public Health TUBERCULOSIS TREATMENT WITH MOBILE-PHONE MEDICATION REMINDERS IN NORTHERN THAILAND Piyada Kunawararak 1, Sathirakorn Pongpanich 2, Sakarin Chantawong 1, Pattana

More information

Prevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011

Prevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011 Original Research Prevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011 Hoa Binh Nguyen, ab Nhung Viet Nguyen, ac Huong Thi Giang Tran,

More information

Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending

Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending EDITORIAL TUBERCULOSIS Bedaquiline: 10 years later, the drug susceptibility testing protocol is still pending Max Salfinger 1 and Giovanni Battista Migliori 2 Affiliations: 1 Dept of Medicine, National

More information

APSR RESPIRATORY UPDATES

APSR RESPIRATORY UPDATES Volume 11 Issue 1 Newsletter Date: January 2019 APSR EDUCATION PUBLICATION Inside this issue: Updates on Treatment in Drug Resistant Tuberculosis World TB Day 2018: the challenge of drug resistant tuberculosis

More information

New Drugs, New Treatments, Shorter Regimens

New Drugs, New Treatments, Shorter Regimens New Drugs, New Treatments, Shorter Regimens Sarah K. Brode, MD MPH FRCP(C) West Park Healthcare Centre, University Health Network, University of Toronto TB Elimination: Back to Basics November 16, 2016

More information

Sirturo: a new treatment against multidrug resistant tuberculosis

Sirturo: a new treatment against multidrug resistant tuberculosis Sirturo: a new treatment against multidrug resistant tuberculosis TB is an on-going problem WHO estimated incidence of new TB cases 2009 Global Tuberculosis Control: WHO report 2010. Available at: http://www.who.int/tb/publications/global_report/2010/en/index.html

More information

Treatment of Tuberculosis, 2017

Treatment of Tuberculosis, 2017 Treatment of Tuberculosis, 2017 Charles L. Daley, MD National Jewish Health University of Colorado Health Sciences Center Treatment of Tuberculosis Disclosures Advisory Board Horizon, Johnson and Johnson,

More information

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility

More information

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012 TB: Management in an era of multiple drug resistance Bob Belknap M.D. Denver Public Health November 2012 Objectives: 1. Explain the steps for diagnosing latent and active TB role of interferon-gamma release

More information

What can be done against XDR-TB?

What can be done against XDR-TB? What can be done against XDR-TB? Dr Matteo Zignol Stop TB Dep. World Health Organization Geneva 16 th Swiss Symposium on tuberculosis Münchenwiler, 22 March 2007 XDR-TB Extensive Drug Resistance XDR =

More information

Tuberculosis: update 2013

Tuberculosis: update 2013 Tuberculosis: update 2013 William R. Bishai, MD, PhD Center for TB Research Division of Infectious Diseases Department of Medicine Johns Hopkins School of Medicine Question 1 A TB speaker at a major conference

More information

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012 LTBI and TB Disease Treatment Cara Christ, MD, MS May 8, 2012 Cara Christ, MD, MS has the following disclosures to make: No conflict

More information

Bastard, M; Sanchez-Padilla, E; Hewison, C; Hayrapetyan, A; Khurkhumal, S; Varaine, F; Bonnet, M. Published by Infectious Diseases Society of America

Bastard, M; Sanchez-Padilla, E; Hewison, C; Hayrapetyan, A; Khurkhumal, S; Varaine, F; Bonnet, M. Published by Infectious Diseases Society of America MSF Field Research Effects of Treatment Interruption Patterns on Treatment Success Among Patients With Multidrug-Resistant Tuberculosis in Armenia and Abkhazia Authors Citation DOI Publisher Journal Rights

More information

Annex 1. Methods for evidence reviews and modelling

Annex 1. Methods for evidence reviews and modelling WHO/HTM/TB/2011.6a. Methods for evidence reviews and modelling Questions for the 2011 update of the Guidelines for the programmatic management of drug-resistant tuberculosis (for Outcomes please see Table

More information

The treatment of patients with initial isoniazid resistance

The treatment of patients with initial isoniazid resistance The treatment of patients with initial isoniazid resistance 2011 INTERTB Meeting, St George s, London Patrick Phillips, MRC Clinical Trials Unit DA Mitchison, AJ Nunn. 21 st October 2011 Outline Background

More information

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female %

I. Demographic Information GENDER NUMBER OF CASES PERCENT OF CASES. Male % Female % San Joaquin County (SJC) in 03, (N=43) County Rate = 6. Cases per 00,000 Population I. Demographic Information Table I-A: TB cases by gender, SJC, 03 (N=43) GENDER NUMBER OF CASES Male 6 60.5% Female 7

More information

XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS. Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma. Pag. 1

XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS. Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma. Pag. 1 XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma Pag. 1 TB estimated incidence in EUR, 2004 Russian Fed. 12 th among the 22 TB high-burden

More information

Failure to Implement the Plan to Eliminate TB in the US: Implications in the Era of Declining Resources

Failure to Implement the Plan to Eliminate TB in the US: Implications in the Era of Declining Resources Failure to Implement the Plan to Eliminate TB in the US: Implications in the Era of Declining Resources Sustaining Public Health Capacity in an Age of Austerity Forum on Microbial Threats Board on Global

More information

Treatment outcomes of multidrug-resistant tuberculosis in Switzerland

Treatment outcomes of multidrug-resistant tuberculosis in Switzerland Published 4 December 04, doi:0.444/smw.04.405 Cite this as: Swiss Med Wkly. 04;44:w405 Treatment outcomes of multidrug-resistant tuberculosis in Switzerland Peter Helbling a, Ekkehardt Altpeter a, Jean-Marie

More information

New Drug Evaluation: Bedaquiline. Month/Year of Review: January 2014 End date of literature search: September 1, 2013

New Drug Evaluation: Bedaquiline. Month/Year of Review: January 2014 End date of literature search: September 1, 2013 Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119

More information

Evolution of XDR-TB. A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal

Evolution of XDR-TB. A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal Evolution of XDR-TB in KwaZulu-Natal A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal Drug resistance among culture positive TB cases by South African

More information

MDR TB. Jaime C. Montoya MD, MSc

MDR TB. Jaime C. Montoya MD, MSc MDR TB Jaime C. Montoya MD, MSc Definitions of MDRTB and XDRTB Historical background of the problem Global and Philippine Data on MDRTB Risk Factors Diagnosis Treatment Research Gaps Guidelines for the

More information

Clinical Trials Lecture 4: Data analysis

Clinical Trials Lecture 4: Data analysis Clinical Trials Lecture 4: Data analysis Dick Menzies, MD Respiratory Epidemiology and Clinical Research Unit Montreal Chest Institute TB Research methods course July 17, 2014 Lecture 4: Data analysis

More information

Role of RNTCP in the management MDR-TB

Role of RNTCP in the management MDR-TB Kamdar DJ, Shah NA, Patel DJ, Parmarr H. Role of RNTCP in the management of MDR-TB. IAIM, 2015; 2(7): 1-5. Original Research Article Role of RNTCP in the management of MDR-TB Deepali J Kamdar 1, Neha A

More information

NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY

NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY NEW DRUGS FOR TUBERCULOSIS: THE NEED, THE HOPE AND THE REALITY Neil W. Schluger, M.D. Professor of Medicine, Epidemiology and Environmental Health Sciences Columbia University Global tuberculosis incidence

More information

Definitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013

Definitions and reporting framework for tuberculosis 2013 revision. Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 Definitions and reporting framework for tuberculosis 2013 revision Dennis Falzon Global Forum of Xpert MTB/RIF Implementers Annecy 17 April 2013 2-year revision process WHO/HTM/TB/2013.2 2 www.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf

More information

Tuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012

Tuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally

More information

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018 Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million

More information

Cronicon EC BACTERIOLOGY AND VIROLOGY RESEARCH. Research Article Multidrug Resistant Tuberculosis Cure Predictors

Cronicon EC BACTERIOLOGY AND VIROLOGY RESEARCH. Research Article Multidrug Resistant Tuberculosis Cure Predictors Cronicon OPEN ACCESS EC BACTERIOLOGY AND VIROLOGY RESEARCH Research Article Multidrug Resistant Tuberculosis Cure Predictors Vinod Namana 1,2 * and Pankaj Mathur 3 1 Department of Cardiology, Maimonides

More information

Upcoming TB Alliance Studies. CPRT DST Review September, 2014

Upcoming TB Alliance Studies. CPRT DST Review September, 2014 Upcoming TB Alliance Studies CPRT DST Review September, 2014 STAND PaMZ Ph 3 STAND: Phase 3 Trial of the Pa-M-Z Regimen Participants with newly diagnosed smear positive DS- and MDR-TB DS Pa(100mg)-M-Z

More information

Treatment Outcomes among Patients with Extensively Drug-Resistant Tuberculosis: Systematic Review and Meta-Analysis

Treatment Outcomes among Patients with Extensively Drug-Resistant Tuberculosis: Systematic Review and Meta-Analysis MAJOR ARTICLE Treatment Outcomes among Patients with Extensively Drug-Resistant Tuberculosis: Systematic Review and Meta-Analysis Karen R. Jacobson, 1 Dylan B. Tierney, 1 Christie Y. Jeon, 2 Carole D.

More information

Factors Associated with Multidrugresistant Tuberculosis: Comparison of Patients Born Inside and Outside of the Czech Republic

Factors Associated with Multidrugresistant Tuberculosis: Comparison of Patients Born Inside and Outside of the Czech Republic The Journal of International Medical Research 2010; 38: 1156 1163 [first published online as 38(3) 26] Factors Associated with Multidrugresistant Tuberculosis: Comparison of Patients Born Inside and Outside

More information

Laboratory Diagnosis for MDR TB

Laboratory Diagnosis for MDR TB Laboratory Diagnosis for MDR TB Neha Shah MD MPH Centers for Disease Control and Prevention Division of Tuberculosis Elimination California Department of Public Health Guam March 07 Objectives Describe

More information

Optimising patient care in MDR TB with existing molecular screening tests in high burden countries

Optimising patient care in MDR TB with existing molecular screening tests in high burden countries Optimising patient care in MDR TB with existing molecular screening tests in high burden countries Camilla Rodrigues MD Consultant Microbiologist Hinduja Hospital,India Outline What is the best empiric

More information

Authors: Samuels, Joel; Sood, Aashna; Khan, Faiz; Johnston, James. Sponsor: Michael Smith Foundation for Health Research

Authors: Samuels, Joel; Sood, Aashna; Khan, Faiz; Johnston, James. Sponsor: Michael Smith Foundation for Health Research Title: Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-Analysis-An update Registration: To be registered in Prospero Authors: Samuels, Joel; Sood, Aashna; Khan, Faiz;

More information

A tale of two settings: the role of the Beijing genotype in the epidemiology of MDR-TB.

A tale of two settings: the role of the Beijing genotype in the epidemiology of MDR-TB. ERJ Express. Published on September 13, 2013 as doi: 10.1183/09031936.00140513 A tale of two settings: the role of the Beijing genotype in the epidemiology of MDR-TB. Helen R. Stagg a,b,c, *, Ted Cohen

More information

Update on Management of

Update on Management of Update on Management of DR TB Definitions Presumptive MDR-TB A patient suspected of drug-resistant TB, based on RNTCP criteria for submission of specimens for drug-susceptibility testing MDR-TB Case A

More information

The Clinical Characteristics and Predictors of Treatment Success of Pulmonary Tuberculosis in Homeless Persons at a Public Hospital in Busan

The Clinical Characteristics and Predictors of Treatment Success of Pulmonary Tuberculosis in Homeless Persons at a Public Hospital in Busan Korean J Fam Med. 2012;33:372-380 http://dx.doi.org/10.4082/kjfm.2012.33.6.372 The Clinical Characteristics and Predictors of Treatment Success of Pulmonary Tuberculosis in Homeless Persons at a Public

More information

NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis

NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis NATIONAL TUBERCULOSIS CONTROL PROGRAMME- SCC AREA Quarterly Report on New and Retreatment Cases of Tuberculosis Patients registered during quarter* of 20 Name of area No.# Name of the Reporter Signature:

More information

Patient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD

Patient History 1. Patient History 2. Social History. The Role of Surgery in the Management of TB. Reynard McDonald, MD & Paul Bolanowski, MD Patient History 1 The Role of Surgery in the Management of TB Reynard McDonald, MD & Paul Bolanowski, MD September 16, 2010 42 y/o AA male was initially diagnosed with pansensitive pulmonary TB in 1986

More information

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area Rapid communications Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area C Ködmön (csaba.kodmon@ecdc.europa.eu)

More information

Treatment of Drug Susceptible Tuberculosis

Treatment of Drug Susceptible Tuberculosis American Thoracic Society / Centers for Disease Control / Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug Susceptible On behalf of the writing committee Payam Nahid,

More information

TB: A Supplement to GP CLINICS

TB: A Supplement to GP CLINICS TB: A Supplement to GP CLINICS Chapter 10: Childhood Tuberculosis: Q&A For Primary Care Physicians Author: Madhukar Pai, MD, PhD Author and Series Editor What is Childhood TB and who is at risk? India

More information

Tuberculosis: The Big Picture And Challenge of Drug-resistance

Tuberculosis: The Big Picture And Challenge of Drug-resistance 5 th APHL National Conference on Laboratory Aspects of Tuberculosis August 11-13, 2008 San Diego, California Tuberculosis: The Big Picture And Challenge of Drug-resistance RADM Kenneth G. Castro, M.D.

More information

Information Note. WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis

Information Note. WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis Information Note WHO call for patient data on the treatment of multidrug- and rifampicin resistant tuberculosis In order to ensure that the upcoming comprehensive revision of WHO policies on treatment

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis American Thoracic Society, CDC, and Infectious Diseases Society of America Please note: An erratum has been published for this article. To view the erratum, please click here.

More information

DRUG RESISTANCE IN TUBERCULOSIS

DRUG RESISTANCE IN TUBERCULOSIS DRUG RESISTANCE IN TUBERCULOSIS INTRODUCTION Up to 50 million people may be infected with drug-resistant resistant TB.* Hot zones of MDR-TB such as Russia, Latvia, Estonia, Argentina and the Dominican

More information

Effectiveness of DOTS regime in terms of cure, failure, default and relapse in the treatment of TB patients

Effectiveness of DOTS regime in terms of cure, failure, default and relapse in the treatment of TB patients International Journal of Advances in Medicine Jahnavi K et al. Int J Adv Med. 2018 Feb;5(1):170-174 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20180079

More information